EA202190249A1 - Пептидные соединения и их терапевтическое применение - Google Patents
Пептидные соединения и их терапевтическое применениеInfo
- Publication number
- EA202190249A1 EA202190249A1 EA202190249A EA202190249A EA202190249A1 EA 202190249 A1 EA202190249 A1 EA 202190249A1 EA 202190249 A EA202190249 A EA 202190249A EA 202190249 A EA202190249 A EA 202190249A EA 202190249 A1 EA202190249 A1 EA 202190249A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- therapeutic application
- peptide compounds
- dexamethasone
- mice
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Описаны выделенные пептиды, способные снижать количество индуцированной дексаметазоном потери массы селезенки и/или тимуса у мышей, а также их применение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL26055518 | 2018-07-11 | ||
PCT/IL2019/050774 WO2020012478A2 (en) | 2018-07-11 | 2019-07-10 | Peptide compounds and therapeutic uses of same |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190249A1 true EA202190249A1 (ru) | 2021-05-21 |
Family
ID=69141375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190249A EA202190249A1 (ru) | 2018-07-11 | 2019-07-10 | Пептидные соединения и их терапевтическое применение |
Country Status (15)
Country | Link |
---|---|
US (2) | US11912790B2 (ru) |
EP (1) | EP3820882A2 (ru) |
JP (2) | JP7395517B2 (ru) |
KR (1) | KR20210045397A (ru) |
CN (1) | CN112351989B (ru) |
AU (1) | AU2019300567A1 (ru) |
BR (1) | BR112020024748A2 (ru) |
CA (1) | CA3100961A1 (ru) |
CO (1) | CO2021001290A2 (ru) |
EA (1) | EA202190249A1 (ru) |
IL (1) | IL280101A (ru) |
MX (1) | MX2021000264A (ru) |
SG (1) | SG11202012773QA (ru) |
WO (1) | WO2020012478A2 (ru) |
ZA (1) | ZA202100587B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11912790B2 (en) | 2018-07-11 | 2024-02-27 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL272074A (en) * | 2020-01-15 | 2021-07-29 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
JPS4843906B1 (ru) * | 1970-08-11 | 1973-12-21 | ||
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO1997044447A2 (en) * | 1996-05-03 | 1997-11-27 | President And Fellows Of Harvard College | Transcriptional activation system, activators, and uses therefor |
GB9711148D0 (en) * | 1997-05-31 | 1997-07-23 | Peptide Therapeutics Ltd | Human MAFA |
EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
US6726895B2 (en) | 2001-04-03 | 2004-04-27 | Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
US20040204340A1 (en) | 2003-04-11 | 2004-10-14 | Guilford Pharmaceuticals, Inc. | Polyprolyl inhibitors of cyclophilin |
EP2578226B1 (en) | 2004-08-23 | 2017-10-25 | Yeda Research And Development Co., Ltd. | Peptide for treating amyotrophic lateral sclerosis |
KR20070100832A (ko) * | 2005-02-01 | 2007-10-11 | 아테뉴온, 엘엘씨 | 항혈관신생 phscn 펩티드를 함유하는 조성물 |
US7704953B2 (en) | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
US8212001B2 (en) * | 2009-09-17 | 2012-07-03 | Ramot At Tel-Aviv University Ltd. | Peptides for the treatment of oxidative stress related disorders |
WO2011126882A2 (en) * | 2010-03-30 | 2011-10-13 | American Type Culture Collection | Therapeutic peptides and their derivatives and therapeutic uses thereof |
EP2593595B1 (en) | 2010-07-16 | 2020-03-11 | Avantgen, Inc. | Novel peptides and uses thereof |
US9157103B2 (en) * | 2010-12-23 | 2015-10-13 | Shell Oil Company | Gene disruptants producing fatty acyl-CoA derivatives |
CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
US20140271666A1 (en) * | 2013-03-14 | 2014-09-18 | Immune Pharmaceuticals Ltd. | Use of anti-eotaxin antibodies for treating inflammatory bowel disease |
CN104045703B (zh) * | 2013-03-15 | 2021-04-06 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
US8802633B1 (en) | 2013-03-18 | 2014-08-12 | Board Of Regents, The University Of Texas System | Autophagy-inducing peptide analogs |
CN107001442B (zh) * | 2014-07-15 | 2021-04-27 | 耶路撒冷希伯来大学伊森姆研究发展公司 | Cd44的分离的多肽及其应用 |
US9453061B2 (en) * | 2014-08-06 | 2016-09-27 | Brown University | Method and compositions for treatment of calcineurin-related diseases |
BR112017022845A2 (pt) | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
WO2017011338A1 (en) | 2015-07-10 | 2017-01-19 | President And Fellows Of Harvard College | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use |
EP3820882A2 (en) | 2018-07-11 | 2021-05-19 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
IL272074A (en) | 2020-01-15 | 2021-07-29 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
-
2019
- 2019-07-10 EP EP19752749.2A patent/EP3820882A2/en active Pending
- 2019-07-10 CA CA3100961A patent/CA3100961A1/en active Pending
- 2019-07-10 EA EA202190249A patent/EA202190249A1/ru unknown
- 2019-07-10 MX MX2021000264A patent/MX2021000264A/es unknown
- 2019-07-10 CN CN201980041027.6A patent/CN112351989B/zh active Active
- 2019-07-10 US US17/254,867 patent/US11912790B2/en active Active
- 2019-07-10 SG SG11202012773QA patent/SG11202012773QA/en unknown
- 2019-07-10 JP JP2020573032A patent/JP7395517B2/ja active Active
- 2019-07-10 AU AU2019300567A patent/AU2019300567A1/en active Pending
- 2019-07-10 WO PCT/IL2019/050774 patent/WO2020012478A2/en unknown
- 2019-07-10 KR KR1020217004105A patent/KR20210045397A/ko unknown
- 2019-07-10 BR BR112020024748-0A patent/BR112020024748A2/pt unknown
-
2021
- 2021-01-11 IL IL280101A patent/IL280101A/en unknown
- 2021-01-27 ZA ZA2021/00587A patent/ZA202100587B/en unknown
- 2021-02-05 CO CONC2021/0001290A patent/CO2021001290A2/es unknown
-
2023
- 2023-11-29 JP JP2023201767A patent/JP2024026217A/ja active Pending
-
2024
- 2024-02-26 US US18/586,715 patent/US20240190919A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11912790B2 (en) | 2018-07-11 | 2024-02-27 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
Also Published As
Publication number | Publication date |
---|---|
SG11202012773QA (en) | 2021-01-28 |
AU2019300567A1 (en) | 2021-02-25 |
MX2021000264A (es) | 2021-05-12 |
US11912790B2 (en) | 2024-02-27 |
CO2021001290A2 (es) | 2021-02-26 |
WO2020012478A2 (en) | 2020-01-16 |
BR112020024748A2 (pt) | 2021-03-23 |
US20240190919A1 (en) | 2024-06-13 |
JP2024026217A (ja) | 2024-02-28 |
WO2020012478A3 (en) | 2020-02-20 |
JP7395517B2 (ja) | 2023-12-11 |
IL280101A (en) | 2021-03-01 |
ZA202100587B (en) | 2022-07-27 |
US20210261615A1 (en) | 2021-08-26 |
CA3100961A1 (en) | 2020-01-16 |
JP2021531246A (ja) | 2021-11-18 |
CN112351989A (zh) | 2021-02-09 |
KR20210045397A (ko) | 2021-04-26 |
CN112351989B (zh) | 2024-03-26 |
EP3820882A2 (en) | 2021-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
EA202092945A1 (ru) | Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии | |
EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
EA202092306A1 (ru) | Анти-cd24 композиции и их применения | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
BR112018071200A2 (pt) | terapia genética para o tratamento da hemofilia a | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
MX2021013417A (es) | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. | |
EA202090184A3 (ru) | Пептидные композиции и способы использования | |
EA201990822A1 (ru) | Иммуномодулирующие слитые белки | |
PH12019501108A1 (en) | Anti-gitr anti-binding protein and methods of use thereof | |
EA202190249A1 (ru) | Пептидные соединения и их терапевтическое применение | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
CL2019003167A1 (es) | Proteínas de unión al antígeno anti-jagged1. | |
MX2021000163A (es) | Proteina de union al antigeno anti-steap1. | |
BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso | |
EA202191758A1 (ru) | Пептиды для лечения и профилактики диабета и связанных с ним заболеваний | |
EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
EA201991738A1 (ru) | Новые соединения (иммунорелины) | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
EA202191081A1 (ru) | Новые раковые антигены и сопутствующие способы | |
EA201890035A1 (ru) | Иммунотерапевтические режимы дозирования, включающие помалидомид и антитело к cs1 для лечения рака | |
BR112018006820A2 (pt) | anticorpos anti-psa (5a10) humanizados | |
BR112022009587A2 (pt) | Anticorpo anti-pcsk9 e uso do mesmo |